Ipsen Stock: 6.47% Weekly Gain Driven by Improved Results and Raised Targets
Ipsen's stock closed the week at €121.80, marking a 6.47% increase, contrasting with the relative stability of Parisian indices. This weekly performance significantly outperformed the CAC 40 (+0.45%) and the SBF 120 (+0.53%). Over the year, the stock has shown a 5.64% increase, confirming a gradual recovery over several months.
Technical Analysis and Market Behavior
The price of €121.80 is precisely at the identified technical resistance level, suggesting that the stock is currently testing a critical threshold. Trading volumes, analyzed through money flow, indicate positive buying pressure with a coefficient of 0.20, reflecting increased market participant interest during this period. Monthly volatility stands at 8.32%, a moderate level that shows relatively controlled price movements despite the weekly rise. A beta of 0.03 highlights the stock's low correlation with overall market fluctuations, typical for pharmaceutical stocks with specific business models. The stock is now comfortably above its moving averages: the 50-day average is at €116.25, which is 4.77% below the current price, while the 200-day average is at €109.15, marking a difference of 11.60%. This technical configuration indicates a strong underlying bullish trend that has strengthened in recent weeks. Bollinger Bands frame the stock between €111.08 and €121.10, with the current price touching the upper boundary, signaling an extension of the bullish movement in the upper part of its volatility channel.
Financial Performance and Strategic Developments
On Tuesday, October 22, Ipsen reported its results for the first nine months of 2025, revealing a revenue of €2.73 billion, up 9.6% in reported figures and 12.1% at constant exchange rates. In the third quarter alone, sales reached €915 million, marking an acceleration with a growth of 13.7% at constant exchange rates. This momentum is supported by the company's three therapeutic areas, with notable performances from Iqirvo, Bylvay, and Somatuline, despite the introduction of generic versions of lanreotide. These announcements were accompanied by a second upward revision of the annual targets for the year. The pharmaceutical company now anticipates revenue growth of about 10% at constant exchange rates for the entirety of 2025, up from a previous forecast of over 7%. The current operating margin is also revised upwards, expected at around 35% of total revenue, compared to a previous target of over 32%. The group justifies these new outlooks by a slower-than-anticipated erosion of Somatuline sales due to generics and an acceleration in the growth of the rest of the portfolio. On the same day, Ipsen announced the definitive agreement to acquire ImCheck Therapeutics, a French company specializing in immuno-oncology therapies. This transaction, valued at €350 million and expected to close by the end of the first quarter of 2026, adds a Phase II asset described as first-in-class in the oncology field to the portfolio. The stock reacted positively to all these announcements, gaining 5.31% during the session on October 22.
Technical Indicators and Future Outlook
Technically, the Relative Strength Index stands at 65, a level that reflects a bullish momentum without yet reaching the traditionally set overbought zone of 70. The MACD shows a value of 0.58, confirming the positive trend observed over several weeks. The configuration of moving averages, with a widening gap between the MM50 and MM200, validates the strength of the ongoing bullish trend. The technical support is located at €111.50, which is 9.26% below the current price, providing a safety margin before a potential pullback. The stock's position in contact with its resistance at €121.80 is now the major focus: consolidation at this level or a breakthrough will determine the short-term direction.
